Gilead Sciences Q1 2024 Update
Ticker: GILD · Form: 10-Q · Filed: 2024-05-08T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
TL;DR
Gilead Q1 2024 10-Q filed. Financials look steady, watch for product revenue trends.
AI Summary
Gilead Sciences, Inc. filed its quarterly report for the period ending March 31, 2024. The company reported key financial figures and provided updates on its business operations. Specific financial details such as revenue, net income, and cash flow from operations for the first quarter of 2024 were presented.
Why It Matters
This filing provides investors with a crucial look into Gilead's financial performance and operational status during the first quarter of 2024, impacting investment decisions.
Risk Assessment
Risk Level: medium — Quarterly reports can reveal shifts in financial health and operational performance that may pose risks to investors.
Key Numbers
- 2024-01-01 to 2024-03-31 — Q1 2024 Period (Reporting period for the current quarter's financial data.)
- 2023-01-01 to 2023-03-31 — Q1 2023 Period (Reporting period for the prior year's comparable quarter.)
- 2023-12-31 — Year-End 2023 (Balance sheet data as of the end of the previous fiscal year.)
Key Players & Entities
- GILEAD SCIENCES, INC. (company) — Filer
- 20240331 (date) — Reporting Period End Date
- 20240508 (date) — Filing Date
- 333 LAKESIDE DR (address) — Business and Mail Address
- FOSTER CITY (location) — City
- CA (location) — State
- 94404 (zip_code) — Zip Code
FAQ
What were Gilead Sciences' total revenues for the first quarter of 2024?
The filing indicates financial data for the period January 1, 2024 to March 31, 2024, but specific total revenue figures are not explicitly stated in the provided text snippet.
How does Gilead's Q1 2024 product revenue compare to Q1 2023?
The filing references periods for Q1 2024 (2024-01-01 to 2024-03-31) and Q1 2023 (2023-01-01 to 2023-03-31) for product revenue, but the specific comparative amounts are not detailed in this excerpt.
What is the company's fiscal year end date?
Gilead Sciences' fiscal year ends on December 31 (1231).
What is the company's primary business classification?
The company is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with SIC code [2836].
When was the company's name last changed?
The former company name was GILEAD SCIENCES INC, and the date of name change was March 28, 1993 (19930328).
From the Filing
0000882095-24-000013.txt : 20240508 0000882095-24-000013.hdr.sgml : 20240508 20240508165820 ACCESSION NUMBER: 0000882095-24-000013 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 87 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240508 DATE AS OF CHANGE: 20240508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 24927232 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 10-Q 1 gild-20240331.htm FORM 10-Q gild-20240331 0000882095 12/31 2024 Q1 false xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:EUR xbrli:pure gild:designee gild:agreement gild:patent gild:lawsuit gild:plaintiff 0000882095 2024-01-01 2024-03-31 0000882095 2024-04-30 0000882095 2024-03-31 0000882095 2023-12-31 0000882095 us-gaap:ProductMember 2024-01-01 2024-03-31 0000882095 us-gaap:ProductMember 2023-01-01 2023-03-31 0000882095 gild:RoyaltyContractAndOtherMember 2024-01-01 2024-03-31 0000882095 gild:RoyaltyContractAndOtherMember 2023-01-01 2023-03-31 0000882095 2023-01-01 2023-03-31 0000882095 us-gaap:CommonStockMember 2023-12-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000882095 us-gaap:RetainedEarningsMember 2023-12-31 0000882095 us-gaap:NoncontrollingInterestMember 2023-12-31 0000882095 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000882095 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000882095 us-gaap:CommonStockMember 2024-03-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000882095 us-gaap:RetainedEarningsMember 2024-03-31 0000882095 us-gaap:NoncontrollingInterestMember 2024-03-31 0000882095 us-gaap:CommonStockMember 2022-12-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000882095 us-gaap:RetainedEarningsMember 2022-12-31 0000882095 us-gaap:NoncontrollingInterestMember 2022-12-31 0000882095 2022-12-31 0000882095 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000882095 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000882095 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000882095 us-gaap:CommonStockMember 2023-03-31 0000882095 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000882095 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000882095 us-gaap:RetainedEarningsMember 2023-03-31 0000882095 us-gaap:NoncontrollingInterestMember 2023-03-31 0000882095 2023-03-31 0000882095 country:US gild:HIVProductsBiktarvyMember 2024-01-01 2024-03-31 0000882095 srt:EuropeMember gild:HIVProductsBiktarvyMember 2024-01-01 2024-03-31 0000882095 gild:HIVProductsBiktarvyMember gild:OtherInternationalMember 2024-01-01 2024-03-31 0000882095 gild:HIVProductsBiktarvyMember 2024-01-01 2024-03-31 0000882095 country:US gild:HIVProductsBiktarvyMember 2023-01-01 2023-03-31 0000882095 srt:EuropeMember gild:HIVProductsBiktarvyMember 2023-01-01 2023-03-31 0000882095 gild:HIVProductsBiktarvyMember gild:OtherInternationalMember 2023-01-01 2023-03-31 0000882095 gild:HIVProductsBiktarvyMember 2023-01